公司概述
Biogen Inc. operates as a leading entity within the healthcare sector, specifically specializing in the discovery, development, manufacturing, and delivery of therapies across the United States, Europe, Germany, Asia, and international markets. The company focuses on producing treatments for complex neurological conditions, including multiple sclerosis with drugs like TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI, as well as SPINRAZA for spinal muscular atrophy and SKYCLARYS for Friedreich's ataxia. As a Drug Manufacturer - General, its business model relies on proprietary intellectual property and clinical trial execution to bring specialized solutions to patients globally. The organization employs approximately 7,500 individuals and maintains a substantial market capitalization of $25.99 billion, reflecting its established position in the pharmaceutical landscape. These valuation metrics and revenue streams indicate that Biogen commands a significant asset base and holds a prominent role in a highly regulated industry where patient outcomes and regulatory approvals dictate long-term viability.
财务健康
The company reported a trailing twelve-month revenue of $9.89 billion and generated a net income of $1.29 billion, while its EBITDA reached $3.60 billion. The substantial gap between the $9.89 billion revenue and the $1.29 billion net income reveals a cost structure heavily influenced by high operating expenses, research and development costs, and potentially significant depreciation or amortization of intangible assets common in drug manufacturing. Despite the net income figure, the company demonstrated robust operational efficiency with an EBITDA of $3.60 billion, highlighting strong cash generation capabilities before capital expenditures and interest obligations. Free cash flow stood at $1.98 billion, which signifies a high degree of financial flexibility allowing the firm to service debt, fund R&D, or pursue strategic acquisitions without immediate external financing. The company holds $3.82 billion in cash against total debt of $6.66 billion, resulting in a debt-to-equity ratio of 36.47, which suggests a leveraged balance sheet given that debt exceeds cash reserves. However, the current ratio of 2.68 indicates strong short-term liquidity, as current assets are more than double current liabilities, ensuring the ability to meet short-term obligations comfortably. Return on Equity is 7.4% and Return on Assets is 6.1%, metrics that provide insight into management's effectiveness in generating profits from shareholders' equity and the total asset base, respectively, though these rates reflect the capital-intensive nature of the pharmaceutical sector.
估值评估
Biogen Inc. trades with a trailing P/E ratio of 20.17 and a forward P/E ratio of 11.03, where the significant difference implies that the market expects a sharp increase in earnings in the future to justify the current multiple. The price-to-book ratio stands at 1.42, indicating that the market values the company at a moderate premium over its book value, suggesting confidence in the quality of its assets and future earning potential. Alternative valuation metrics such as the price-to-sales ratio of 2.63 and an EV/EBITDA of 8.00 provide context, suggesting the company is valued relative to its revenue generation and enterprise earnings power at levels comparable to peers in the healthcare industry. Over the past year, the stock price ranged between a 52-week low of $110.04 and a 52-week high of $202.41; without the exact current share price, the position relative to this range is defined by this historical volatility corridor. The beta value of 0.16 indicates that the stock exhibits very low price volatility relative to the broader market, moving significantly less than the S&P 500 and offering a lower-risk profile in terms of systemic market fluctuations.
Growth & Income
Biogen reported a revenue growth rate of -7.1% year-over-year, while earnings growth for the trailing twelve months is listed as N/A, indicating that current earnings data does not reflect a clear year-over-year expansion trajectory in the most recent reporting period. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means the firm reinvests all of its available earnings back into research and development, acquisitions, or operational improvements rather than distributing cash to shareholders. This strategy prioritizes long-term therapeutic expansion and pipeline development over immediate income generation for investors. Consequently, the overall growth and income profile of Biogen is characterized by a contraction in revenue volume combined with a complete retention of earnings, positioning the company for potential future growth dependent on new product launches or market share gains rather than current yield.